# QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer

> **NCT03127124** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **NantPharma, LLC**

## Conditions studied

- Pancreatic Adenocarcinoma Metastatic

## Interventions

- **DRUG:** NANT-008
- **DRUG:** Fluorouracil Injectable Product
- **DRUG:** Avastin Injectable Product
- **DRUG:** Leucovorin Calcium Injection
- **DRUG:** Eloxatin Injectable Product

## Key facts

- **NCT ID:** NCT03127124
- **Lead sponsor:** NantPharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-02-27
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn due to no enrollment
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03127124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03127124, "QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03127124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*